Literature DB >> 12368583

Effects of stress and behavioral interventions in hypertension: the rise and fall of omapatrilat.

Thomas G Pickering1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12368583      PMCID： PMC8099358          DOI： 10.1111/j.1524-6175.2002.01506.x

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN： 1524-6175            Impact factor:   3.738


× No keyword cloud information.
  10 in total

1.  Vasopeptidase inhibitors: a bradykinin link.

Authors:  Fernando Boix
Journal:  Lancet       Date:  2002-03-30       Impact factor: 79.321

2.  Results from late-breaking clinical trial sessions at the American College of Cardiology 51st Annual Scientific Session.

Authors:  Eric S Williams; John M Miller
Journal:  J Am Coll Cardiol       Date:  2002-07-03       Impact factor: 24.094

3.  Omapatrilat versus lisinopril: efficacy and neurohormonal profile in salt-sensitive hypertensive patients.

Authors:  V M Campese; K C Lasseter; C M Ferrario; W B Smith; M C Ruddy; C E Grim; R D Smith; R Vargas; M F Habashy; O Vesterqvist; C L Delaney; W C Liao
Journal:  Hypertension       Date:  2001-12-01       Impact factor: 10.190

4.  Baseline Characteristics and Early Blood Pressure Control in the CONVINCE Trial.

Authors:  Henry R. Black; William J. Elliott; James D. Neaton; Gregory Grandits; Patricia Grambsch; Richard H. Grimm; Lennart Hansson; Yves Lacoucière; James Muller; Peter Sleight; Michael A. Weber; William B. White; Gordon Williams; Janet Wittes; Alberto Zanchetti; T. Daniel Fakouhi; Robert J. Anders
Journal:  Hypertension       Date:  2001-01       Impact factor: 10.190

5.  The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT): clinical center recruitment experience.

Authors:  J T Wright; W C Cushman; B R Davis; J Barzilay; P Colon; D Egan; T Lucente; C Nwachuku; S Pressel; F H Leenen; J Frolkis; R Letterer; S Walsh; J N Tobin; G E Deger
Journal:  Control Clin Trials       Date:  2001-12

6.  Efficacy and safety of omapatrilat with hydrochlorothiazide for the treatment of hypertension in subjects nonresponsive to hydrochlorothiazide alone.

Authors:  K Ferdinand; R Saini; A Lewin; L Yellen; J A Barbosa; E Kushnir
Journal:  Am J Hypertens       Date:  2001-08       Impact factor: 2.689

7.  Design of the Omapatrilat in Persons with Enhanced Risk of Atherosclerotic events (OPERA) trial.

Authors:  John B Kostis; Stuart Cobbe; Colin Johnston; Ian Ford; Michael Murphy; Michael A Weber; Henry R Black; Pierre Francois Plouin; Daniel Levy; Guiseppe Mancia; Pierre Larochelle; Rainer E Kolloch; Michael Alderman; Luis Miguel Ruilope; Björn Dahlöf; John M Flack; Robert Wolf
Journal:  Am J Hypertens       Date:  2002-02       Impact factor: 2.689

8.  Vasopeptidase inhibitor reduces inhospital costs for patients with congestive heart failure: results from the IMPRESS trial. Inhibition of Metallo Protease by BMS-186716 in a Randomized Exercise and Symptoms Study in Subjects With Heart Failure.

Authors:  Eric L Eisenstein; Charlotte L Nelson; Teresa A Simon; Allison L Smitten; Pablo Lapuerta; Daniel B Mark
Journal:  Am Heart J       Date:  2002-06       Impact factor: 4.749

9.  Candoxatril, a neutral endopeptidase inhibitor: efficacy and tolerability in essential hypertension.

Authors:  E G Bevan; J M Connell; J Doyle; H A Carmichael; D L Davies; A R Lorimer; G T McInnes
Journal:  J Hypertens       Date:  1992-07       Impact factor: 4.844

10.  Trends in the prevalence, awareness, treatment, and control of hypertension in the adult US population. Data from the health examination surveys, 1960 to 1991.

Authors:  V L Burt; J A Cutler; M Higgins; M J Horan; D Labarthe; P Whelton; C Brown; E J Roccella
Journal:  Hypertension       Date:  1995-07       Impact factor: 10.190
  10 in total
  7 in total

Review 1.  Comprehensive review of cardiovascular toxicity of drugs and related agents.

Authors:  Přemysl Mladěnka; Lenka Applová; Jiří Patočka; Vera Marisa Costa; Fernando Remiao; Jana Pourová; Aleš Mladěnka; Jana Karlíčková; Luděk Jahodář; Marie Vopršalová; Kurt J Varner; Martin Štěrba
Journal:  Med Res Rev       Date:  2018-01-05       Impact factor: 12.944

Review 2.  Targeting Metalloenzymes for Therapeutic Intervention.

Authors:  Allie Y Chen; Rebecca N Adamek; Benjamin L Dick; Cy V Credille; Christine N Morrison; Seth M Cohen
Journal:  Chem Rev       Date:  2018-09-07       Impact factor: 60.622

Review 3.  Renin angiotensin aldosterone inhibition in the treatment of cardiovascular disease.

Authors:  Carlos M Ferrario; Adam E Mullick
Journal:  Pharmacol Res       Date:  2017-05-29       Impact factor: 7.658

4.  Recent clinical trials with omapatrilat: new developments.

Authors:  Anne Zanchi; Marc Maillard; Michel Burnier
Journal:  Curr Hypertens Rep       Date:  2003-08       Impact factor: 5.369

5.  Incidence and predictors of angioedema in elderly hypertensive patients at high risk for cardiovascular disease: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

Authors:  Linda B Piller; Charles E Ford; Barry R Davis; Chuke Nwachuku; Henry R Black; Suzanne Oparil; Tamrat M Retta; Jeffrey L Probstfield
Journal:  J Clin Hypertens (Greenwich)       Date:  2006-09       Impact factor: 3.738

Review 6.  Angiotensin receptor-neprilysin inhibitors: clinical potential in heart failure and beyond.

Authors:  Jagdeep S S Singh; Chim C Lang
Journal:  Vasc Health Risk Manag       Date:  2015-06-01

Review 7.  Potential mechanisms of beneficial effect of sacubitril/valsartan on glycemic control.

Authors:  Jelena P Seferovic; Scott D Solomon; Ellen W Seely
Journal:  Ther Adv Endocrinol Metab       Date:  2020-12-25       Impact factor: 3.565
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.